Half-Year 2022 Financial Performance
Divisional Performance
Continued momentum across Divisions
Continued strong Biologics
growth with some mix dilution
Small Molecules impacted by
phasing of customer deliveries,
but strong margin from mix
Lonza
Financial Results by Division H1 2022
CORE
Sales growth
CER1
EBITDA
Margin
change AER²
margin
Biologics
26.2%
37.3%
(0.9)ppts
Small Molecules
(21.3)%
29.9%
2.6ppts
Strong performance in Cell &
Gene helped by a one-off
Capsules & Health Ingredients
with strong performance,
mitigating inflation and supply
constraints
1 Constant Exchange Rate. Comparison vs. H1 2021
2 Actual Exchange Rate. Comparison vs. H1 2021
Cell & Gene
23.4%
22.4%
6.3ppts
Capsules & Health
4.0%
35.2%
Ingredients
(0.2)ppts
Lonza
16.8%
33.1%
(0.2)ppts
CORE definition: See appendix
13View entire presentation